DaunoXome Cleared For Kaposi's Sarcoma

Oncology NEWS International Vol 5 No 5, Volume 5, Issue 5

BOULDER, Colorado--NeXstar Pharmaceutical's DaunoXome (dauno-rubicin citrate liposome injection) has received FDA approval for use as primary therapy for advanced HIV-associated Kaposi's sarcoma (KS).

BOULDER, Colorado--NeXstar Pharmaceutical's DaunoXome (dauno-rubicincitrate liposome injection) has received FDA approval for useas primary therapy for advanced HIV-associated Kaposi's sarcoma(KS).

In the company-sponsored phase III trial, conducted at 13 US andCanadian centers and involving 227 patients with advanced HIV-associatedKS, Dauno-Xome was found to have efficacy comparable to the three-drugregimen of Adria-mycin, bleomycin, and vincristine (ABV).

Average survival was 342 days for patients on DaunoXome vs 291days for those on ABV. Side effects such as neu-ropathy and alopeciawere reduced significantly with use of DaunoXome.